Results 1 to 10 of about 3,124 (157)

Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells [PDF]

Scientific Reports, 2017
HIV prevention research is focused on combining antiretrovirals (ARV) and progestin contraceptives to prevent HIV infection and pregnancy. The possibility that progestins compromise ARV anti-HIV activity prompted us to evaluate the effects of progestins ...
Zheng Shen, Marta Rodriguez-Garcia, Mickey V. Patel, Jack Bodwell, Angela D. M. Kashuba, Charles R. Wira   +5 more
doaj   +3 more sources

Targeting SIRT-1/AMPK/Nrf2 Signaling Pathway by Tenofovir Protected Against Cyclophosphamide-Induced Nephrotoxicity and Cardiotoxicity in Rats [PDF]

Pharmaceutics
Background/Objectives: Cyclophosphamide (CYC) is a commonly used alkylating agent for treating various cancers and autoimmune disorders. However, its use is often hampered by serious side effects, affecting multiple organs.
Yousef S. Alresheedi, Omnia A. Nour, Manar A. Nader, Marwa S. Zaghloul   +3 more
doaj   +2 more sources

Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study. [PDF]

PLoS Medicine
BackgroundOral emtricitabine/tenofovir disoproxil fumarate (F/TDF) preexposure prophylaxis (PrEP) effectiveness against HIV acquisition highly depends on adherence.
Kenneth K Mugwanya, Matilda Saina, Nelly R Mugo, Samantha MaWhinney, Mary Morrow, Torin T Schaafsma, Deborah Donnell, David V Glidden, Kenneth Ngure, Clare E Brown, Elena A Rechkina, Bhavna H Chohan, Linxuan Wu, Elex Hill, Eric Koome, Nina Akelo, Sarah Mbaire, Susan A Morrison, Mary Kibatha, Irene Njeru, Marianne Muriithi, Corwin Coppinger, Lane Bushman, Jared M Baeten, Peter L Anderson, Women Benchmark Study Team   +25 more
doaj   +2 more sources

Cost and clinical flow of point‐of‐care urine tenofovir testing for treatment monitoring among people living with HIV initiating ART in South Africa [PDF]

Journal of the International AIDS Society
Introduction Point‐of‐care (POC) urine tenofovir (TFV) tests can provide timely information regarding antiretroviral therapy (ART) adherence to support management of HIV treatment in clinics.
Melody Wang, Pravikrishnen Moodley, Mlungisi Khanyile, Elliot Bulo, Makhosazane Zondi, Keshani Naidoo, Yukteshwar Sookrajh, Jienchi Dorward, Monica Gandhi, Nigel Garrett, Paul K. Drain, Monisha Sharma   +11 more
doaj   +2 more sources

Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue

Pharmaceutics, 2022
Background: HIV-1 pre-exposure prophylaxis (PrEP) has focused predominantly on protective efficacy in receptive sex, with limited research on the dosing requirements for insertive sex.
Laura Else, Sujan D. Penchala, Azure-Dee Pillay, Thabiso B. Seiphetlo, Limakatso Lebina, Christian Callebaut, Suks Minhas, Roland Morley, Tina Rashid, Neil Martinson, Julie Fox, Saye Khoo, Carolina Herrera   +12 more
doaj   +1 more source

Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

Frontiers in Cellular and Infection Microbiology, 2022
BackgroundA relationship between the vaginal microbiota and tenofovir (TFV) concentrations and activity after topical administration has been previously reported.ObjectiveCONRAD A15-138 was a randomized, placebo-controlled Phase I study aimed at ...
Andrea R. Thurman, Jacques Ravel, Pawel Gajer, Mark A. Marzinke, Louise A. Ouattara, Terry Jacot, M. Melissa Peet, Meredith R. Clark, Gustavo F. Doncel   +8 more
doaj   +1 more source

Tenofovir vaginal film as a potential MPT product against HIV-1 and HSV-2 acquisition: formulation development and preclinical assessment in non-human primates

Frontiers in Reproductive Health, 2023
Tenofovir (TFV) is an adenosine nucleotide analog with activity against HIV and HSV-2. Secondary analyses of clinical trials evaluating TFV gel as pre-exposure prophylaxis (PrEP) for HIV have shown that gel formulations of TFV provide significant ...
Sravan Kumar Patel, Sravan Kumar Patel, Hrushikesh Agashe, Hrushikesh Agashe, Dorothy L. Patton, Yvonne Sweeney, May A. Beamer, Craig W. Hendrix, Sharon L. Hillier, Sharon L. Hillier, Lisa C. Rohan, Lisa C. Rohan, Lisa C. Rohan   +12 more
doaj   +1 more source

Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells. [PDF]

PLoS ONE, 2013
Tenofovir (TFV) has been widely used for pre-exposure prophylaxis of HIV-1 infection with mixed results. While the use of TFV in uninfected individuals for prevention of HIV-1 acquisition is actively being investigated, the possible consequences of TFV ...
Nabanita Biswas, Marta Rodriguez-Garcia, Sarah G Crist, Zheng Shen, Jack E Bodwell, John V Fahey, Charles R Wira   +6 more
doaj   +1 more source

Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study

PLoS ONE, 2022
Multipurpose prevention technologies (MPTs), which prevent sexually transmitted infection(s) and unintended pregnancy, are highly desirable to women.
Andrea R. Thurman, Vivian Brache, Leila Cochon, Louise A. Ouattara, Neelima Chandra, Terry Jacot, Nazita Yousefieh, Meredith R. Clark, Melissa Peet, Homaira Hanif, Jill L. Schwartz, Susan Ju, Mark A. Marzinke, David W. Erikson, Urvi Parikh, Betsy C. Herold, Raina N. Fichorova, Elizabeth Tolley, Gustavo F. Doncel   +18 more
doaj   +2 more sources

Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel [PDF]

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2018
Objective: We describe and compare the local and systemic pharmacokinetics (PK) of tenofovir (TFV) and TFV-diphosphate (TFV-DP) in healthy premenopausal (PRE) and postmenopausal (POST) women using TFV 1% gel and correlate local PK with other mucosal end points. Methods: PRE (n = 20)
Thurman, Andrea Ries, Chandra, Neelima, Yousefieh, Nazita, Kimble, Thomas, Anderson, Sharon M., Cottrell, Mackenzie, Sykes, Craig, Kashuba, Angela, Schwartz, Jill L., Doncel, Gustavo F.   +9 more
openaire   +2 more sources